1 Introduction The infusion of T cells engineered to express chimeric antigen receptors (CARs) was first authorized by the United States Food and Drug Administration (FDA) to treat B-cell acute lymphoblastic leukemia (ALL) in the year 2017 (1, 2). Although CAR-T technology has demonstrated success in treating several cancer types (3), it presents certain limitations such as occasionally causing cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) (4).
